TAG Mail 10 January 2019

The purpose of TAGMail is to assist TAG members identify and share relevant information for their professional practice. Members are encouraged to routinely forward TAGMail to others who they believe would benefit from this information such as colleagues in the same hospital department if they are not already receiving TAGMail. TAGMail as a standing agenda item in clinical pharmacists’ and other clinicians’ meetings may help facilitate discussion of contemporary and emerging medicines and practice. NSW TAG may be contacted via email nswtag@stvincents.com.au or by calling 02 8382 2852.

Wishing you a very successful and Happy New Year from all of us at NSW TAG.

NSW TAG ACTIVITIES
**Life Saving Drug Registers (LSDRs)**
- The Antivenom and Antidote LSDRs (Bulk updated Dec 2018) are now available on our website. Thank you to those hospitals who responded with their current stockholdings. Any outstanding sites to please provide an update to us as soon as possible. It is recommend that members refer to the website for the latest version of the registers as the information may be updated from time to time before the next annual bulk update.

**New email discussions:**
- New packaging of Nystatin Oral Drops – closes 14th January 2019
- Documentation of IPU decision making in eMR – closes 24th January 2019

**DTC Decision-Making Register**
- DTC decisions in NSW A1-A3 hospitals up to December 2018 uploaded to member’s section of website

CONSULTATIONS (new additions in bold)
**CEC**
- Draft: Clinical Handover Policy- provide feedback by 14th January 2019
- Draft: Health Literacy Framework - closes 14 February 2019 - link

**NHMRC**
- Public consultation for following modules- provide feedback by 6 February 2019: Organisation and budgeting; Guideline Development Group; Forming the questions; Identifying the evidence; Synthesising evidence; Assessing risk of bias; Assessing certainty of evidence; Implementation; Dissemination.

**TGA**
- Consultation: Remaking Therapeutic Goods Order No. 78 - Standard for Tablets and Capsules and reintroducing pills into the remade Order - Closing date: 8 February 2019
- Consultation: Regulatory options for appropriate access and safety controls for alkyl nitrites Closing date: 15 January 2019 - link
- Consultation: Review of Therapeutic Goods Order 54 - Standards for Disinfectants; and associated guidance Closing date: 12 February 2019 - link

REPORTS AND PUBLICATIONS – AUSTRALIA
- Guidelines on Perioperative Management of Anticoagulant and Antiplatelet Agents - link
- Intravenous Unfractionated Heparin Recommended Standard - link
**MIMS Monthly Update - January 2019**

- New medications:
  - Avanafil (Spedra®) for erectile dysfunction in adult males.
  - Cerliponase alfa (rch) for CLN2 disease, also known as TPP1 deficiency
  - Durvalumab (rch) (Imfinzi®) for locally advanced or metastatic urothelial carcinoma with disease progression during or following platinum-containing chemotherapy, or disease progression within 12 months of neoadjuvant or adjuvant treatment with platinum-containing chemotherapy.
  - Safinamide (mesilate) (Xadago®) for fluctuating idiopathic Parkinson's disease (PD) in adults as add-on therapy to a regimen that includes levodopa.
  - Tafenoquine (succinate) (Kodatef®): antimalarial that kills the developing asexual, developing exoerythrocytic, and latent hypnozoites of malaria parasites

**NSW Health Intrnet**
- Safety Notice 021/18: Discontinuation of nifedipine (twice daily products) and patient safety risks with alternative

**Pharmacy Council of NSW**
- Amendment to the Poisons and Therapeutic Goods Regulation 2008 to regulate the following as Type A drugs of addiction:
  1. cannabis (when in Schedule 8)
  2. tetrahydrocannabinols (when in Schedule 8)
  3. unregistered drugs of addiction (including compounded Schedule 8 medicines).

**TGA**
- Medicine shortages guidance and resources - Information for sponsors and health professionals - link
  - New AusPARs:
    - Peramivir (Rapivab®) indicated for the treatment of acute influenza infection in adults and children 2 years and older who have been symptomatic for no more than two days.

**Victorian Institute of Forensic Medicine**
- Clinical Communiqué – December

REPORTS AND PUBLICATIONS – INTERNATIONAL

**Agency for Healthcare Research and Quality (AHRQ) USA**
- A web application to involve patients in the medication reconciliation process: a user-centered usability and usefulness study - link

**BNF/BNFC eNewsletter December 2018**
- Three new drug monographs have been added to BNF as well as dose changes for: antibiotics for Lyme disease, dabigatran, gabapentin, influenza vaccine, roflumilast, and tapentadol. Updated guidance on management of Lyme disease and rheumatoid arthritis also included.

**Canadian Agency for Drugs and Technologies in Health**
- Rapid Sequence Induction Agents for Emergency Intubation: Comparative Clinical Effectiveness and Guidelines - link
  - Strategies for the Management of Latent or Previously Treated Tuberculosis: Clinical Effectiveness, Cost-Effectiveness, and Guidelines - link
  - Continuous Glucose Monitoring for Patients with All Diabetes Types: Clinical Effectiveness and Guidelines - link
  - Atypical Injectable Antipsychotics for Schizophrenia or Bipolar Disorder: A Review of Clinical Effectiveness and Cost-Effectiveness - link
  - Subcutaneous Butterfly Lines for Medication Administration: Clinical Effectiveness, Cost-Effectiveness, and Guidelines - link

**European Medicines Agency (EMA)**
- Human medicines highlights 2018 - link
**Health Canada**
- Health Product InfoWatch - *December 2018*

**National Institute for Health and Clinical Excellence (NICE) UK**
- Lenvatinib for untreated advanced hepatocellular carcinoma – guidance *(TA551)*
- Liposomal cytarabine–daunorubicin for untreated acute myeloid leukaemia – guidance *(TA552)*
- Pembrolizumab for adjuvant treatment of resected melanoma with high risk of recurrence – guidance *(TA553)*
- Pancreatic cancer- Quality standard *(QS177)*
- Tisagenlecleucel for treating relapsed or refractory B-cell acute lymphoblastic leukaemia in people aged up to 25 years – guidance *(TA554)*
- Bronchiectasis (non-cystic fibrosis), acute exacerbation: antimicrobial prescribing- guidance *(NG117)*
- Renal and ureteric stones: assessment and management- guidance *(NG118)*

**Royal College of General Practitioners UK (RCGP)**
- Guidance for GPs on cannabis-based medicines and products - [link](#)

**Specialist Pharmacy Services**
- New Medicines Newsletter December 2018 - [link](#)
- Medicines Use and Safety Update January 2019 - [link](#)
- Which opioids can be used in renal impairment? - [link](#)
- What is the risk of interaction between opioids and monoamine oxidase inhibitors (MAOIs)? - [link](#)
- What is the first choice antidepressant for patients with renal impairment? - [link](#)
- NICE Bites: Prostatitis - [link](#)
- Which medicines require extra care when switching between liquid and tablet/capsule formulations? - [link](#)
- NOACs and Antidepressants – What are the risks of using these together and how should these risks be managed? - [link](#)

**Therapeutics Initiative Canada**
- New drug for cystic fibrosis: Regulatory approval, clinical uncertainty? - [link](#)

**MEDICATION SAFETY**
**electronic Medicines Compendium (eMC)**
- Revised SPCs
  - Ciprofloxacin: epidemiologic studies report an increased risk of aortic aneurysm and dissection after intake of fluoroquinolones, particularly in the older population.
  - Valproic acid / sodium valproate: Haemorrhage (common) and vasculitis (uncommon) listed as potential adverse effects.
  - Kisplyx™ and Lenvima™ *(lenvatinib mesilate)*: Pneumothorax and nephrotic syndrome added as new adverse drug reactions (uncommon frequency).
  - Cerezyme™ *(imiglucerase)*: Advises that no case of overdose has been reported. Doses up to 240 U/kg body weight once every two weeks have been used.
  - Diprivan™ *(propofol)*: Section 4.5 corrected to state that profound hypotension (not hypertension as in previous SPC) has been reported following anaesthetic with propofol in patients treated with rifampicin.

**Food and Drug Administration (FDA) USA**
- FDA safety announcement about increased risk of ruptures or tears in the aorta blood vessel with *fluoroquinolone antibiotics* in certain patients. FDA now require a new warning about this risk to be added to the prescribing information and patient Medication Guide for all fluoroquinolones
- New approvals
  - First and Only Digital Inhaler with Built-In Sensors – ProAir® Digihaler™ *(albuterol sulfate 117 mcg)* Inhalation Powder
Tagraxofusp-erzs (Elzonris™) for the treatment of blastic plasmacytoid dendritic cell neoplasm
- Levodopa inhalation powder (Inbrija™) for intermittent treatment of "off" episodes in people with Parkinson's disease who are already taking an oral carbidopa-levodopa regimen
- Andexanet alfa (Andexxa™) a factor Xa reversal agent

**Health Canada – MedEffect Notice
- Xarelto® (rivaroxaban): Increase in all-cause mortality, thromboembolic and bleeding events in patients after transcatheter aortic valve replacement

**MIMS Monthly Update - January 2019
- New Contraindications
  -- Atazanavir (sulfate)/cobicistat (Evotaz®) should not be used in combination with glecaprevir/pibrentasvir because of the increased risk of ALT elevations due to an increase in glecaprevir and pibrentasvir plasma concentrations. Co-administration of Evotaz® with the antipsychotic lurasidone is contraindicated due to the potential for serious and/or life-threatening events or loss of virologic response and possible resistance.
  -- Doxycycline hyclate (hydrochloride) (Doryx®): concurrent use of tetracycline and methoxyflurane has been reported to result in fatal renal toxicity.
  -- Fosamprenavir (calcium) (Telzir)/ritonavir: must not be administered concomitantly with lurasidone.
  -- Imipramine hydrochloride (Tofranil®): contraindicated in children under 18 years of age for the treatment of depression or other psychiatric disorders.

**ACI
- Social Determinants of Health – web resource - link
- Consumer Enablement: A Clinician's Guide - link
- Projects: Implementing and Embedding the National Surgical Quality Improvement Program in NSW - link

**Australian Prescriber
- Podcast Episode 40 – Alcohol detox at home

**Australian Department of Health
- Head to Health (H2H) – resource for patients to find Australian digital mental health information, resources and services - link

**Cardiac Society of Australia and New Zealand (CSANZ) Annual Scientific Meeting 2018 Conference Review
- Heart, Lung and Circulation: Combining Forces: Nurse Practitioner and Clinical Pharmacist Led Heart Failure Clinic and its Impact on Titration Rates and Hospital Readmission - link

**CEC
- Potential third NSW AMS Forum in 2019: Suggestions for session topics and/or speakers are welcome, and would assist in planning this potential event – please email suggestions to CEC-AMS@health.nsw.gov.au.
- CEC and Emergency Care Institute, ACI
  - Recommended naloxone supplies to treat carfentanil overdoses
  Memo to Local Health Districts/ Specialty Health Networks to ensure facilities with Emergency Departments have adequate stock of naloxone to treat patients with carfentanil overdose. Doses of up to 10 mg of naloxone may be required.

**Health Services Research Association Australian and New Zealand
- The Pros and Cons of Patient Reported Outcome Measures (PROMs) and Patient Reported Experience Measures (PREMs) – link

**Health Literacy Hub - Healthliteracyhub.org.au
An initiative of Western Sydney LHD in collaboration with the University of Sydney
**ISQua**
- Survey on the impact of vulnerabilities on patient safety - link
- ISQua and the Lucian Leape Foundation launch new Patient Safety Fellowship opens on 6th December and closes 15th February 2019 - link

**Musculoskeletal Australia Free Webinar Series, register for topics including:**
- Diagnosing and managing psoriatic arthritis
  Tue 26 Feb, 7 - 8pm, Dr Marie Feletar, Rheumatologist, Melbourne
- Diagnosing and managing fibromyalgia,
  Wed 8 May, 7 - 8pm, Dr Emma Guymen, Rheumatologist, Monash Medical Centre
- Common foot problems and MSK conditions
  Tue 25 Jun, 7 - 8pm, Prof Deborah Turner, Western Sydney University
- Understanding and managing low back pain
  Wed 21 Aug, 7 - 8pm, A/Prof Manuela Ferreira, The University of Sydney
- Managing knee osteoarthritis
  Wed 23 Oct, 7 - 8pm, Dr Adam Castricum, Sport and Exercise Physician
- The safe and appropriate use of medicines
  Tue 19 Nov, 7 - 8pm, Dr Anthony Tassone, Victorian President, Pharmacy Guild of Australia

**National Centre for Antimicrobial Stewardship - Journal Club**
Registration for the 2019 NCAS Journal Club webinar series is now open

**NPS MedicineWise**
- Low back pain podcast

**TGA**
- Alkyl nitrites - public meetings - Sydney 31 Jan, Melbourne 7 Feb
- Review of the Narcotic Drugs Act 1967 - public meetings - Sydney 5 Feb, Brisbane 6 Feb, Melbourne 8 Feb
- Webinar: The role of the TGA in digital health - 7 February

**PAPERS OF INTEREST**

**American Journal of Cardiology**
- Meta-Analysis of Effects of Digoxin on Survival in Patients with Atrial Fibrillation or Heart Failure: An Update - link

**Anesthesia and Analgesia**
- Regional Analgesia Added to General Anesthesia Compared with General Anesthesia Plus Systemic Analgesia for Cardiac Surgery in Children: A Systematic Review and Meta-analysis of Randomized Clinical Trials - link

**Annals of Intensive Care**
- Caring for the critically ill patients over 80: a narrative review - link

**Annals of Internal Medicine**
- Fracture Risk after Initiation of Use of Canagliflozin: A Cohort Study - link
- Cost-Effectiveness of Alirocumab: A Just-in-Time Analysis based on the ODYSSEY Outcomes Trial - link

**British Journal of Clinical Pharmacology**
- A systematic review of clinicians' views and experiences of direct-acting oral anticoagulants in the management of nonvalvular atrial fibrillation - link
- The influence of heart failure on the pharmacokinetics of cardiovascular and non-cardiovascular drugs: a critical appraisal of the evidence - link
- The journey of metformin from glycaemic control to mTOR inhibition and the suppression of tumour growth - link
- Anticholinergic exposure and cognitive decline in older adults: effect of anticholinergic exposure definitions in a 3-year analysis of the multidomain Alzheimer preventive trial (MAPT) study - link
- Prevalence and incidence of prescription opioid analgesic use in Australia - link
- Comparative safety and effectiveness of direct oral anticoagulants in patients with atrial fibrillation in clinical practice in Scotland - link
- A clinical trial on the acute effects of methadone and buprenorphine on actual driving and cognitive function of healthy volunteers - link
- The impact of tacrolimus exposure on extrarenal adverse effects in adult renal transplant recipients - link
- Identification of behaviour change techniques in deprescribing interventions: a systematic review and meta-analysis - link

**British Medical Journal (BMJ)**
- Dual antiplatelet therapy with aspirin and clopidogrel for acute high risk transient ischaemic attack and minor ischaemic stroke: a clinical practice guideline - link
- Use of C-reactive protein to tailor antibiotic use: a systematic review and meta-analysis - link
- Update on the evidence for oral B12 supplements to treat deficiency - link
- Triple inhaled therapy versus dual inhaled therapy for COPD - link
- Stopping, rationalising or optimising antipsychotic drug treatment in people with intellectual disability and/or autism - link
- MI risk associated with naproxen and diclofenac in spondyloarthritis - link
- Association of a label of penicillin allergy with increased risk of MRSA and Clostridium difficile infection - link

**Circulation**
- Metformin Improves Insulin Sensitivity and Vascular Health in Youth with Type 1 Diabetes Mellitus - link
- Tailoring Antiplatelet Therapy Intensity to Ischemic and Bleeding Risk - link
- Clinical Utility of Patient-Reported Outcome Measurement Information System Domain Scales - link

**Cochrane**
- Dual combination therapy versus long-acting bronchodilators alone for chronic obstructive pulmonary disease (COPD): a systematic review and network meta-analysis - link
- Inhaled steroids with and without regular salmeterol for asthma: serious adverse events - link
- Betahistine for tinnitus - link
- Tranexamic acid for patients with nasal haemorrhage (epistaxis) - link
- Alpha-glucosidase inhibitors for prevention or delay of type 2 diabetes mellitus and its associated complications in people at increased risk of developing type 2 diabetes mellitus - link
- Perioperative intravenous ketamine for acute postoperative pain in adults - link
- Uterotonic agents for preventing postpartum haemorrhage: a network meta-analysis - link
- Early discontinuation of antibiotics for febrile neutropenia versus continuation until neutropenia resolution in people with cancer - link
- Iron for the treatment of restless legs syndrome - link
- Acetyl-L-carnitine for patients with hepatic encephalopathy - link
- Disease management interventions for heart failure - link
- Cognitive behavioural therapy plus standard care versus standard care for people with schizophrenia - link
- Psychological therapies for anxiety and depression in children and adolescents with long-term physical conditions - link
- Restriction of salt, caffeine and alcohol intake for the treatment of Ménière's disease or syndrome - link

**European Heart Journal**
- β-blockers, calcium antagonists, and mortality in stable coronary artery disease: an international cohort study - link
- When is it appropriate to stop non-vitamin K antagonist oral anticoagulants before catheter ablation of atrial fibrillation? A multicentre prospective randomized study - [link](#)
- Efficacy and safety of reduced-dose non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation: a meta-analysis of randomized controlled trials - [link](#)
- Clinical outcomes, edoxaban concentration, and anti-factor Xa activity of Asian patients with atrial fibrillation compared with non-Asians in the ENGAGE AF-TIMI 48 trial - [link](#)

**European Journal of Hospital Pharmacy**
- A case report of photodermatoses induced by the antifungal drug terbinafine - [link](#)
- Inpatients' satisfaction towards information received about medicine - [link](#)

**European Journal of Preventive Cardiology**
- Depression, antidepressants, and the risk of non-valvular atrial fibrillation: A nationwide Danish matched cohort study - [link](#)

**European Respiratory Journal**
- Triple therapy versus single and dual long-acting bronchodilator therapy in COPD: a systematic review and meta-analysis - [link](#)

**Internal Medicine Journal**
- The Use of Biologic Agents in the Management of Uveitis - [link](#)

**JAMA**
- Rethinking How Antibiotics Are Prescribed - Incorporating the 4 Moments of Antibiotic Decision Making into Clinical Practice - [link](#)
- Association of Pharmacological Treatments with Long-term Pain Control in Patients with Knee Osteoarthritis - A Systematic Review and Meta-analysis - [link](#)
- Clinical Update - Perioperative Glucose Control in Patients with Diabetes Undergoing Elective Surgery - [link](#)

**JAMA Cardiology**
- Interindividual Variation in Low-Density Lipoprotein Cholesterol Level Reduction with Evolocumab - An Analysis of FOURIER Trial Data - [link](#)
- Estimated 5-Year Number Needed to Treat to Prevent Cardiovascular Death or Heart Failure Hospitalization with Angiotensin Receptor-Nephrilysin Inhibition vs Standard Therapy for Patients With Heart Failure With Reduced Ejection Fraction: An Analysis of Data From the PARADIGM-HF Trial - [link](#)

**JAMA Internal Medicine**
- Association of Parenteral Anticoagulation Therapy with Outcomes in Chinese Patients Undergoing Percutaneous Coronary Intervention for Non–ST-Segment Elevation Acute Coronary Syndrome - [link](#)
- Association of Corticosteroid Treatment with Outcomes in Adult Patients with Sepsis - A Systematic Review and Meta-analysis - [link](#)
- Patient resource: Vitamins and Nutritional Supplements - What Do I Need to Know? - [link](#)
- Association of the Trauma of Hospitalization With 30-Day Readmission or Emergency Department Visit - [link](#)
- Association of Prescribed Opioids with Increased Risk of Community-Acquired Pneumonia among Patients With and Without HIV - [link](#)

**JAMA Network Open**
- US National Trends in Pediatric Deaths from Prescription and Illicit Opioids, 1999-2016 - [link](#)
- Association of Second-line Antidiabetic Medications with Cardiovascular Events among Insured Adults with Type 2 Diabetes - [link](#)
- Assessment of Guideline Discordance with Antimicrobial Prophylaxis Best Practices for Common Urologic Procedures - [link](#)

**JAMA Neurology**
- Association of Rituximab Treatment with Disability Progression among Patients with Secondary Progressive Multiple Sclerosis - [link](#)
**JAMA Paediatrics**  
- Effect of Intranasal Ketamine vs Fentanyl on Pain Reduction for Extremity Injuries in Children - The PRIME Randomized Clinical Trial - [link](#)

**JAMA Psychiatry**  
- Association Between Antidepressant Drug Use and Hip Fracture in Older People Before and After Treatment Initiation - [link](#)

**JAMA Surgery**  
- Association Between Antithrombotic Medication Use after Bioprosthetic Aortic Valve Replacement and Outcomes in the Veterans Health Administration System - [link](#)

**JAMIA (Journal of the American Medical Informatics Association)**  
- Designing a medication timeline for patients and physicians - [link](#)

**Journal of General Internal Medicine**  
- A Systematic Review and Meta-analysis of the Association between Vitamin K Antagonist Use and Fracture - [link](#)

**Lancet**  
- Effects of fluoxetine on functional outcomes after acute stroke (FOCUS): a pragmatic, double-blind, randomised, controlled trial - [link](#)  
- Use of liraglutide and risk of major cardiovascular events: a register-based cohort study in Denmark and Sweden - [link](#)  
- Sofosbuvir–velpatasvir for treatment of chronic hepatitis C virus infection in Asia: a single-arm, open-label, phase 3 trial - [link](#)  
- Safety of elvitegravir, cobicistat, emtricitabine, and tenofovir alafenamide in HIV-1-infected adults with end-stage renal disease on chronic haemodialysis: an open-label, single-arm, multicentre, phase 3b trial - [link](#)  
- Safety and efficacy of nabiximols on spasticity symptoms in patients with motor neuron disease (CANALS): a multicentre, double-blind, randomised, placebo-controlled, phase 2 trial - [link](#)  
- Identifying English Practices that Are High Antibiotic Prescribers Accounting for Comorbidities and Other Legitimate Medical Reasons for Variation - [link](#)  
- Review: Antibiotic allergy - [link](#)  
- Insomnia disorder subtypes derived from life history and traits of affect and personality - [link](#)  
- New pharmacological strategies for protecting kidney function in type 2 diabetes - [link](#)

**New England Journal of Medicine**  
- Fracture Prevention with Zoledronate in Older Women with Osteopenia - [link](#)  
- Haloperidol and Ziprasidone for Treatment of Delirium in Critical Illness - [link](#)  
- Cardiovascular Risk Reduction with Icosapent Ethyl for Hypertriglyceridemia - [link](#)

**National Institute for Health Research (NIHR)**  
- NIHR Signals  
  -- Home-based cardiac rehabilitation for heart failure has high rates of participation - [link](#)  
  -- Thyroid hormone treatment does not help adults with mildly abnormal thyroid tests - [link](#)  
  -- Antidepressants do not help treat depression in people living with dementia - [link](#)  
  -- People leaving hospital after medical illness do not benefit from extended clot reducing treatment - [link](#)

**Pediatrics (American Academy of Pediatrics)**  
- Trends in Outpatient Antibiotic Use in 3 Health Plans - [link](#)  
- Mupirocin for Staphylococcus aureus Decolonization of Infants in Neonatal Intensive Care Units - [link](#)  
- Youth and the Opioid Epidemic - [link](#)
**Prescrire in English**
- Prescrire International issue 199 December 2018 - [link](#)

**Therapeutics and Clinical Risk Management**
- Calcium and vitamin D supplementation with 3-year denosumab treatment is beneficial to enhance bone mineral density in postmenopausal patients with osteoporosis and rheumatoid arthritis - [link](#)

**Thrombosis and Haemostasis**
- The antifibrinolytic and anti-inflammatory effects of multiple doses of oral tranexamic acid in total knee arthroplasty patients: a randomized controlled trial - [link](#)

**UPCOMING EVENTS**
(only recent additions will be listed in TAGMail - please click here for the running list of other upcoming events)
**Digital Health Transformation Summit**
18 - 21 February 2019, Melbourne Convention and Exhibition Centre - [link](#)

**Outpatient Parenteral Antibiotic Therapy (OPAT)/Hospital in The Home (HITH)**
(1 day pre-conference symposium before Antimicrobials 2019) - [link](#)
20th February 2019 9 - 5:30pm, Victor Chang Cardiac Institute, St Vincent’s Hospital, Sydney.

**ACI Telehealth Capability Interest Group (TCIG) Forum**
21 February 2019, 1 - 2pm - [link](#)

**ACI Musculoskeletal Network Forum 2019**
28 February 2019, 9 - 4pm
Kerry Packer Education Centre, Royal Prince Alfred Hospital, Camperdown NSW 2050 - [link](#)

**Rural Innovations Changing Healthcare (RICH) 2019 Forum**
20th March 2019 9 - 3pm
Call for Abstracts is now open, and closes 4th February 2019 - [link](#)

**15th National Rural Health Conference**
24 -27 March 2019, Hotel Grand Chancellor, Hobart, Tasmania - [link](#)

You are receiving this email because you or a workplace colleague has requested TAG Mail. NSW TAG analyses uptake of TAG Mail (email openings and clicks on specific contents) in order to optimise the TAG Mail service for our members and colleagues. By requesting TAG Mail, you are also agreeing to have your data (email address, country of abode) captured. All information obtained is used in accordance with NSW Health Privacy Policy. Please contact NSW TAG at nswtag@stvincents.com.au if you have any questions regarding this.